Sangamo BioSciences | SGMO - Operating Profit

Stock Price
0.35
Daily Change
0 0%
Monthly
-20.11%
Yearly
-58.40%
Q1 Forecast
0.32

Sangamo BioSciences reported $-33.51M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Alaunos Therapeutics USD -1.19M 148K Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Amgen USD 3.96B 464M Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
Pfizer USD 4.65B 3.99B Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025